EN
English✓简体中文繁體中文TürkçeEspañolBahasa MelayuBahasa IndonesiaTiếng ViệtPortuguêsРусский

Only complete language versions are shown.

Let’s talk

After Cell or Gene Therapy: What Does Long-Term Follow-Up Check, and Who Is Responsible After You Return Home?

EastMedGo

Before leaving the treatment center, ask your treatment team for a written follow-up plan tailored to you and your treatment, and ask your local doctor to confirm which parts they can take over. Every test should have a date, location, a person responsible for reviewing the results, and a contact for abnormal results. Receiving medical records or an appointment confirmation alone does not mean the clinical handover is complete.

This guide is for patients and families who live across borders after receiving, or preparing to receive, cell or gene therapy. Risks and follow-up periods vary by treatment. Your original treatment team should confirm your arrangements based on the product or research protocol and your individual circumstances.

Key Points

  • Ask your treatment team to assess when you can return home and whether you can fly. Early monitoring and caregiver requirements cannot be determined by a general timeline.
  • Ask your original team to specify how treatment effectiveness, risks after treatment, and your underlying condition each need to be monitored. Do not apply one product’s follow-up period to every treatment.
  • For serious symptoms, seek local emergency care or call local emergency services first, then notify the treatment center as soon as possible. You do not need to prove that treatment caused the symptoms first.
  • The responsibilities of the receiving doctor, original center, and research team should follow a written plan confirmed by both sides. If no one has taken over yet, ask your original team to help arrange interim care.

What to Confirm Before Returning Home

Discuss with your treatment team whether you are well enough to travel, what care you will need during the journey, and whether the place where you plan to live can provide the medical care you need. Ask the center to put your individual requirements for staying nearby, having a caregiver, driving, and returning home in writing. If your condition changes, ask the team to reassess you. Do not decide to leave solely because you have booked a flight.

Next, take the plan to your local doctor and ask whether each item can be arranged as required. In particular, confirm which tests can be done locally, whether they require a designated laboratory or specific method, which must be done at the original center or elsewhere, and the required language, format, units, and secure transmission method for reports. Clarify who will care for you while you wait for appointments and how prescriptions and medicines will be continued. If local tests do not meet protocol requirements, ask the doctors on both sides and the research team to discuss alternatives. Do not skip tests yourself.

What Long-Term Follow-Up Checks

The follow-up plan should answer four types of questions: have early reactions after treatment resolved; have blood cells, the immune system, and affected organs recovered; is the underlying condition controlled; and are there delayed changes that need long-term observation? These stages may overlap. Tests and timing depend on the product, disease, previous treatments, and your individual circumstances. Long-term follow-up monitors your health; it does not necessarily mean continuing the original treatment.

Ask your treatment team to explain which category your treatment belongs to, which risks need attention, and which tests address them:

  • Genetically modified cell or gene-editing therapy: Integration of certain vectors or gene editing may carry risks of delayed genetic changes and tumors. Whether specialized testing is needed depends on the actual product and circumstances. For specific CD19- or BCMA-targeted autologous CAR-T products it has approved, the US FDA recommends lifelong monitoring for secondary malignancies. This is not a uniform follow-up period for all products in China. FDA guidance; FDA safety information
  • In vivo gene therapy: Monitoring plans differ according to the vector, target organ, and how long gene expression lasts. Ask whether monitoring of the target organ, immune responses, or treatment effects is needed, and whether there are any product-specific precautions. European Medicines Agency
  • Other cell therapies: Risks cannot be assumed to be the same for autologous products, allogeneic products, or different cell products. Ask your doctor to explain whether infection, immune problems, or organ problems need monitoring, based on the cell source, how treatment was given, preparatory treatment, and adverse reactions that have already occurred. A treatment without genetic modification still requires attention to treatment risks.

Include separate parts of the plan for disease monitoring, treatment safety, infection and immune recovery, and routine chronic disease management and preventive care. Tests may include blood tests, organ function tests, disease imaging, or other specialized tests; your doctor will explain which are appropriate for you. Ask when infection-prevention medicines, vaccines, and other restrictions should be reviewed. Do not stop medicines yourself. Abnormal findings may also be related to the underlying condition, preparatory treatment, or other causes, so have a doctor assess them first.

Which Treatment Records to Take With You

Ask your original center to prepare a handover summary, and keep the complete medical records and original-language documents. The receiving doctor may need:

  • The exact product or technology name, treatment date, method of administration, and batch number if available. If you participated in research, record the study name, registration number, center, and responsible investigator. If the study is still blinded, ask the team to explain what information can be provided.
  • Your diagnosis, previous treatments, preparatory treatment, current medicines, and allergy history; the course of treatment, significant adverse reactions, unresolved issues, and recent results.
  • Applicable patient information, discharge records, follow-up plan, and alert card. If the treatment involves a vector, gene editing, or a cell source, ask the team to provide the technical information the receiving doctor needs. You do not need to guess this yourself.
  • Daytime and emergency contact details for the original center, research or manufacturer contacts, the receiving doctor where you live, and the person responsible for tracking pending results.

First ask the receiving doctor which translations and original documents are needed, and send them through a secure method accepted by both sides. Ask the receiving team to confirm that the documents have arrived, are readable, and have been passed to the responsible doctor. If the new doctor needs more information, ask them to list what is missing, then contact the original center. Keep a copy that you can access over the long term.

Assign Each Follow-Up Task to a Specific Person

Ask your original center to complete the table below for your treatment, then have the receiving doctor confirm it. For anything not yet settled, write “To be arranged” and name the person responsible. Do not leave cells blank.

What to confirm What to record
Next and later follow-up visits Dates or permitted time windows, locations, purpose and types of tests, and whether you must attend in person
Local tests and results Which facility will order and perform tests, who receives the reports, who reviews them and when, and whom to contact if results are pending or there is no response
Abnormal findings and ongoing care Which situations require same-day contact and which require immediate emergency care; who adjusts treatment and prescribes ongoing medicines
Original center or research team Who receives reports, explains treatment- or protocol-related questions, and receives safety event reports; a backup contact if they cannot be reached
Payment and practical arrangements Who pays for follow-up visits, tests, specialized testing, emergency care, travel, and translation; whether insurance covers them and whether prior authorization is needed

Ask the team to distinguish tasks for disease control, treatment safety, and routine healthcare. For treatments that may affect immunity, blood cells, or organ function, clarify which monitoring, infection precautions, and vaccination arrangements you personally need. Also confirm any restrictions on fertility, pregnancy, breastfeeding, donation, or other activities according to the specific treatment and protocol. Do not apply another patient’s rules to yourself.

Remote consultations can be used to discuss reports or symptoms, but the treatment team and research protocol must determine which visits require an in-person assessment and which tests cannot be replaced by local testing. If you have difficulty attending follow-up, sending results back, or traveling, contact the original team and local doctor early so they can arrange rescheduling or alternatives together.

You can send this directly to the receiving doctor: “I received [product or study name] on [date]. The original center recommends [tests and time window], and the reports need to be reviewed by [name or team]. Can you take over ordering these tests and providing clinical assessments? Have you received and read the summary? If you cannot take over, please tell me what is still missing or which department I can contact.”

What to Do About New Symptoms or Abnormal Results

If you have difficulty breathing, chest pain, seizures, confusion, severe bleeding, or another critical condition, go to a local emergency department or call local emergency services immediately. Carry your treatment summary and alert card, and tell the emergency doctor the treatment name, date, and original center’s contact details. Notify the original center as soon as possible after emergency care has been initiated. Do not wait for a reply from another country.

Before you leave the country, ask the original center to write down your personal thresholds and time limits for contacting them about signs of infection, such as fever or chills, based on your specific treatment and stage of recovery. They should also specify where to get an urgent local assessment if you cannot reach them. Do not apply another product’s temperature threshold to yourself. For other new symptoms or abnormal results, contact your local doctor and original team according to your personal plan. If the original center cannot be reached or its reply is delayed, and symptoms persist or worsen, contact a local doctor for assessment. Seek immediate care in an emergency. When reporting an event, record when it occurred, the symptoms, test results, and any hospitalization or treatment. Doctors will assess whether it is related to treatment. You do not need to prove a causal link before reporting it.

Also promptly tell your local doctor and original team, according to your personal plan, about new issues that are not emergencies but need follow-up, such as a new lump, repeated infections, persistently low blood cell counts, declining function, abnormal liver function, hospitalization, or pregnancy. Ask the team to specify contact time limits and a backup contact in advance.

If you are later diagnosed with a new cancer or experience an event that the protocol requires to be reported, ask your local doctor to contact the original team as soon as possible to find out whether special testing, reporting, or sample arrangements are needed. The clinical team should manage sample collection and treatment decisions. Do not let these arrangements delay necessary assessment or treatment. FDA safety information for specific CAR-T products

What to Do When the Program or Contacts Change

Follow-up arrangements may need to change when treatment or research ends, you move, a doctor leaves, a center closes, or the sponsor changes. Ask the original center in advance who will keep the records, who will receive new safety information and event reports, and which department to contact if you cannot find the contact person. Ask for written details of a backup contact. Notify both teams of changes to your contact details as agreed.

If the center closes or does not respond for a prolonged period, first contact the original hospital’s medical records department, the study lead, or the research ethics committee to ask where the records are held and who the next contact will be. At the same time, ask your local doctor to arrange your current medical care. Do not assume that someone has taken over. Keep unresolved follow-up tasks on the to-do list and agree on a date to ask again.

Frequently Asked Questions

Does every gene therapy require 15 years of follow-up?

No. The US FDA recommends that long-term observation for some investigational gene therapy products be designed according to the product’s risks. Not all products require the same duration. Ask your original team to explain how long you need follow-up and what it should check, based on the specific prescribing information or research protocol. FDA guidance on long-term follow-up after gene therapy

If I feel well, can I stop follow-up checks or preventive medicines?

Discuss this with your treatment team first. Follow-up may monitor changes that do not yet cause obvious symptoms. Whether you need to continue a particular test or medicine depends on your individual circumstances. Do not stop medicines or change doses yourself.

If the study stops giving treatment, does follow-up end too?

Not necessarily. Ask the research team to explain separately the timing and arrangements for stopping treatment, your individual follow-up, and the end of the study. Also ask them to explain the arrangements for continued access to medicine, withdrawal, and referral.

What if a patient no longer wants to continue research follow-up?

Applicable Chinese research ethics rules require participants to be informed that they may withdraw at any time without giving a reason and without unfair treatment. Ethics measures Tell the research team which visits or contacts you want to stop, ask about safety care after withdrawal and how information and samples already collected will be handled, then have your local doctor arrange necessary routine medical care. Research follow-up and routine clinical care can be discussed separately.

What if I miss a test or cannot return to the treatment center?

Tell your original team and local doctor as soon as possible. Explain the original scheduled time, the reason, and your current symptoms. Ask both sides to confirm rescheduling, whether local testing is acceptable, and arrangements while you wait. Seek local emergency care first for critical symptoms.

What if the doctor in my home country is unfamiliar with the product?

Ask the original center to provide product information, a treatment summary, and a professional contact channel so your local doctor can ask questions directly. If the local doctor cannot take over, ask both sides to help find a suitable specialist. Successfully sending documents does not confirm that a doctor has agreed to take over your care.

Whom should I notify if I become pregnant or plan to have children?

Tell your treatment team and the relevant local doctors. Ask whether this product or protocol requires reporting, follow-up, or specific measures. Arrangements may differ for individual patients and their partners. Do not assume that treatment will necessarily affect future children.

Who pays for follow-up checks or complications?

Sponsors and institutions conducting drug clinical trials in China must not charge participants fees related to the clinical trial. Related expenses and reasonable compensation for applicable research are also governed by ethics rules. Regulations for the Implementation of the Drug Administration Law Ask the center to explain how specific items are classified. If there is a dispute, you can check with the ethics committee or relevant authority. Separately verify with the center, insurer, and local healthcare facility who pays for routine care, research-required tests, special testing, treatment of complications, and cross-border travel. Obtain written answers and confirm how long they apply. Payment arrangements during a study cannot automatically be assumed to continue after it ends.

Sources

Date checked: November 6, 2026. These sources apply to different countries, products, and research settings. Your treatment team should confirm your personal plan.

Chat on WhatsAppEmail